GO ID: GO3227
Agency: National Health and Medical Research Council (NHMRC)
Close Date: 05-Feb-2020

Applications to this grant opportunity must propose a clinical trial that addresses a gap in current research and/or knowledge in reproductive cancer.

For the purposes of this grant opportunity, reproductive cancers in women are cancers located in the cervix, uterus, vulva, fallopian tubes, endometrium or ovaries, and in men cancers of the prostate, testicles and penis are within scope.

The objectives of this grant opportunity are to utilise clinical trials to:

− address gaps in research and/or knowledge attributable to reproductive cancer

− deliver outcomes that are a priority for the Australian public, including community engagement and involvement during conceptualisation, development and planned implementation of projects

− provide high-quality evidence of the efficacy of new health treatments, drugs and devices utilising, where appropriate, the research capabilities of existing clinical quality registries

− test the effectiveness of interventions for which a commercial return is unlikely to be achieved due to low patient numbers or where it is not possible to obtain an enforceable intellectual property right

− engage health service delivery partners that will support implementation of study findings into practice, as quickly as possible

− expand clinical trials activity in Australia by supporting new controlled clinical trials or alternatively, where justified, innovative and adaptive trial designs1 and precision medicine trials that take individual genetic variation into account in disease treatment.

To be competitive for funding, applicants must propose to conduct a single clinical trial that delivers against the above objectives. Clinical trials should not have commenced recruitment; however new treatment arms of established Australian and international trials will also be considered.